Stewart Ross - MedImmune | 人才画像

基本信息

浏览量：15

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 106 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Durvalumab with or Without Tremelimumab in Combination with Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes from the Phase 3 POSEIDON Trial

Solange Peters,Byoung Chul Cho,Alexander V. Luft,Jorge Alatorre-Alexander,Sarayut Lucien Geater,Konstantin Laktionov,Dmytro Trukhin,Sang-We Kim, Grygorii M. Ursol,Maen Hussein,Farah Louise Lim,Cheng-Ta Yang,Luiz Henrique Araujo,Haruhiro Saito,Niels Reinmuth, Caitlin Lowery,Helen Mann,Ross Stewart,Haiyi Jiang,Edward B. Garon

Journal of thoracic oncology official publication of the International Association for the Study of Lung Cancer (2024)

引用0浏览0WOS引用

Machine Learning Modeling of Patient Health Signals Informs Long-Term Survival on Immune Checkpoint Inhibitor Therapy

Gerald J. Sun,Gustavo Arango-Argoty,Gary J. Doherty, Damian E. Bikiel, Dejan Pavlovic, Allen C. Chen,Ross A. Stewart,Zhongwu Lai,Etai Jacob

ISCIENCEno. 9 (2024)

引用0浏览0WOS引用

Abstract 7617: Quantitative continuous scoring of PD-L1 for superior patient selection for anti-PD-L1 treatment of locally advanced or unresectable NSCLC

Jan Martin Lesniak, Ina Bisha,Simon Christ,Lina Meinecke,Thomas Padel, Laura Sebastian Monasor,Pallavi Sontakke,Tze Heng Tan,Dasa Medrikova, Andrea Storti,Anatoliy Shumilov,Hadassah Sade,Günter Schmidt,Ross Stewart,Yashaswi Shrestha

Cancer Researchno. 6_Supplement (2024): 7617-7617

引用0浏览0引用

Abstract CT238: Associations of Ctdna Levels During Neoadjuvant Treatment with Pathological Response in Patients with Resectable NSCLC from the Phase 3 AEGEAN Trial

Davina Gale,Zhou Zhu,Zhongwu Lai,Martin Reck, David H. Harpole,Janis M. Taube,Tetsuya Mitsudomi,Maximilian J. Hochmair,Thomas Winder,László Urbán,Jerónimo Rafael Rodríguez‐Cid,Quincy Siu-Chung Chu,Jamie E. Chaft,Ross Stewart,Darren Hodgson,Gary J. Doherty,John V. Heymach

Cancer researchno. 7_Supplement (2024): CT238-CT238

引用0浏览0引用

CTLA4 Blockade Abrogates KEAP1/STK11-related Resistance to PD-(L)1 Inhibitors

Ferdinandos Skoulidis, Haniel A. Araujo, Minh Truong Do,Yu Qian, Xin Sun,Ana Galan Cobo, John T. Le,Meagan Montesion, Rachael Palmer,Nadine Jahchan,Joseph M. Juan,Chengyin Min,Yi Yu,Xuewen Pan,Kathryn C. Arbour,Natalie Vokes, Stephanie T. Schmidt,David Molkentine,Dwight H. Owen,Regan Memmott, Pradnya D. Patil,Melina E. Marmarelis,Mark M. Awad,Joseph C. Murray,Jessica A. Hellyer,Justin F. Gainor, Anastasios Dimou, Christine M. Bestvina,Catherine A. Shu,Jonathan W. Riess,Collin M. Blakely,Chad V. Pecot,Laura Mezquita,Fabrizio Tabbo,Matthias Scheffler,Subba Digumarthy,Meghan J. Mooradian,Adrian G. Sacher, Sally C. M. Lau, Andreas N. Saltos,Julia Rotow, Rocio Perez Johnson, Corinne Liu,Tyler Stewart,Sarah B. Goldberg, Jonathan Killam,Zenta Walther,Kurt Schalper, Kurtis D. Davies, Mark G. Woodcock,Valsamo Anagnostou,Kristen A. Marrone, Patrick M. Forde,Biagio Ricciuti,Deepti Venkatraman,Eliezer M. Van Allen,Amy L. Cummings,Jonathan W. Goldman, Hiram Shaish, Melanie Kier,Sharyn Katz,Charu Aggarwal,Ying Ni, Joseph T. Azok,Jeremy Segal, Lauren Ritterhouse,Joel W. Neal, Ludovic Lacroix,Yasir Y. Elamin, Marcelo V. Negrao, Xiuning Le,Vincent K. Lam,Whitney E. Lewis,Haley N. Kemp,Brett Carter,Jack A. Roth,Stephen Swisher,Richard Lee, Teng Zhou,Alissa Poteete, Yifan Kong, Tomohiro Takehara, Alvaro Guimaraes Paula,Edwin R. Parra Cuentas,Carmen Behrens,Ignacio I. Wistuba,Jianjun Zhang,George R. Blumenschein,Carl Gay,Lauren A. Byers,Don L. Gibbons,Anne Tsao,J. Jack Lee,Trever G. Bivona,D. Ross Camidge, Jhannelle E. Gray, Natasha Lieghl, Benjamin Levy,Julie R. Brahmer,Marina C. Garassino,David R. Gandara,Edward B. Garon,Naiyer A. Rizvi,Giorgio Vittorio Scagliotti,Juergen Wolf,David Planchard,Benjamin Besse,Roy S. Herbst,Heather A. Wakelee,Nathan A. Pennell,Alice T. Shaw,Pasi A. Jaenne,David P. Carbone,Matthew D. Hellmann,Charles M. Rudin,Lee Albacker,Helen Mann, Zhou Zhu,Zhongwu Lai,Ross Stewart,Solange Peters,Melissa L. Johnson, Kwok K. Wong,Alan Huang,Monte M. Winslow,Michael J. Rosen, Ian P. Winters,Vassiliki A. Papadimitrakopoulou,Tina Cascone, Philip Jewsbury,John V. Heymach

NATURE (2024)

引用0浏览0WOSNATURE引用

Abstract 2492: Enhanced patient selection for anti-PD-L1 treatment in metastatic NSCLC with quantitative continuous scoring of PD-L1

Jan Martin Lesniak,Markus Schick,Thomas Kunzke, Federico Pollastri, Juan Pedro Vigueras-Guillén,Harald Hessel,Susanne Haneder,Pallavi Sontakke,Karma DaCosta,Regina Alleze,Hadassah Sade,J Carl Barrett,Günter Schmidt,Ross Stewart

Cancer Researchno. 6_Supplement (2024): 2492-2492

引用0浏览0引用

620 Multimodal Real World Data Reveals Immunogenomic Drivers of Acquired and Primary Resistance to Immune Checkpoint Blockade

Mohamed Reda Keddar, Sebastian Carrasco Pro, Kathleen Burke, Ana Camelo Stewart,Mark Cobbold,Ross Stewart,Sajan Khosla,Ben Sidders,Scott Hammond,Douglas C. Palmer,Jonathan Dry,Martin L. Miller

CANCER RESEARCHno. 6 (2024)

引用0浏览0引用

Abstract PO1-19-10: Durvalumab + datopotamab deruxtecan in patients with PD-L1 positive advanced/metastatic triple-negative breast cancer: Arm 8 of the phase 1b/2, open label, platform BEGONIA study

Peter Schmid,Cynthia Ma,Robert Huisden,Ross Stewart,Katrin Heider,Petra Vuković,Neelima Denduluri

Cancer Researchno. 9_Supplement (2024): PO1-19

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn